SomnoMed (ASX:SOM) said it will absorb the immediate costs from new US tariffs in the immediate term, according to a Monday filing with the Australian bourse.
The company, which manufactures its products in the Philippines, is assessing the evolving impact of the tariffs, the filing said.
SomnoMed reaffirmed its fiscal year revenue guidance of about AU$105 million, with earnings before interest, taxes, depreciation, and amortization expected in the range of AU$7 million to AU$9 million, the filing added.
Shares of the company fell 19% at market close.